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Abstract
Background: Leprosy is a disease of the skin and peripheral nervous system caused by the obligate intracellular bacterium
Mycobacterium leprae. The clinical presentations of leprosy are spectral, with the severity of disease determined by the
balance between the cellular and humoral immune response of the host. The exact mechanisms that facilitate disease
susceptibility, onset and progression to certain clinical phenotypes are presently unclear. Various studies have examined
lipid metabolism in leprosy, but there has been limited work using whole metabolite profiles to distinguish the clinical
forms of leprosy.
Methodology and Principal Findings: In this study we adopted a metabolomics approach using high mass accuracy
ultrahigh pressure liquid chromatography mass spectrometry (UPLC-MS) to investigate the circulatory biomarkers in newly
diagnosed untreated leprosy patients. Sera from patients having bacterial indices (BI) below 1 or above 4 were selected,
subjected to UPLC-MS, and then analyzed for biomarkers which distinguish the polar presentations of leprosy. We found
significant increases in the abundance of certain polyunsaturated fatty acids (PUFAs) and phospholipids in the high-BI
patients, when contrasted with the levels in the low-BI patients. In particular, the median values of arachidonic acid (2-fold
increase), eicosapentaenoic acid (2.6-fold increase) and docosahexaenoic acid (1.6-fold increase) were found to be greater in
the high-BI patients.
Significance: Eicosapentaenoic acid and docosahexaenoic acid are known to exert anti-inflammatory properties, while
arachidonic acid has been reported to have both pro- and anti-inflammatory activities. The observed increase in the levels of
several lipids in high-BI patients may provide novel clues regarding the biological pathways involved in the
immunomodulation of leprosy. Furthermore, these results may lead to the discovery of biomarkers that can be used to
investigate susceptibility to infection, facilitate early diagnosis and monitor the progression of disease.
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Introduction
Leprosy is caused by Mycobacterium leprae, an obligate intracellular
pathogen, which infects the skin and peripheral nerves. M. leprae
invasion of Schwann cells leads to nerve damage, disability and
deformity [1–2]. However, not all infected patients have the same
clinical course. The course of the disease may be punctuated by
spontaneous and/or recurring episodes of immunological imbalanc-
es that need immediate medical attention and immune suppressive
treatment. There are no routine laboratory tests for monitoring
clinical improvement, response to treatment or evolution of drug
resistance, aside from monitoring the reduction of bacillary levels in
skin smears. Even after several decades of multidrug therapy
programs to reduce leprosy transmission, incidence is not declining
at expected rates in some of the most endemic countries [3]. This
persistent incidence in some regions is commonly believed to be due
to undetected and undiagnosed subclinical cases [4].
Leprosy is conventionally described as a spectral disease using
the well-established Ridley-Jopling scheme [5]. At one pole is the
limiting form termed tuberculoid (TT) leprosy. In tuberculoid
leprosy the bacterial load is low due to effective cell mediated
immunity (CMI), and the infection is usually localized to either a
skin patch or nerve trunk. At the site of infection, the immune
response is dominated by Th1 associated pro-inflammatory
cytokines (IFN-c and IL-2) and granuloma formation. The
opposite profile form is lepromatous (LL) leprosy, which shows a
high bacterial load, poor CMI, and is characterized by Th2
associated anti-inflammatory cytokines (IL-4 and IL-10) and
antibody production. Between the poles are borderline tuberculoid
(BT), borderline (BB) and borderline lepromatous (BL).
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the range of susceptibility to clinical outcomes, including metabolic
and immune functions. The individual contributions of host and
bacterium are not yet fully defined, although many human genetic
loci and bacterial components have been implicated in the process
of infection and perturbation of the immune response [6–10]. Host
factors include single nucleotide polymorphisms (SNPs) in genomic
regions associated with a variety of products such as TNF-a, IL-
10, vitamin D receptor (VDR), parkin (PARK2) and parkin co-
regulated gene protein (PACRG) [11–12]. Nutritional and
metabolic factors may also play a role in regulating the host
immune response [13–14]. The pathogen M. leprae is unique in
that its genome has undergone massive decay, particularly in
catabolic pathways and energy generating processes, and is
therefore thought to be highly dependent on the host system for
growth [15]. Novel overlapping mechanisms have been described
by which M. leprae modulates its environment for nutrition and
immune evasion [16].
In this context, where leprosy is a product of complex host-
pathogen relationships, there is a need for modern approaches to
uncover underlying and/or novel biochemical signals that may be
informative regarding those pathways that contribute to disease.
Though leprosy is a disease of the skin and peripheral nerves, there
may be biomarkers in the blood (circulatory biomarkers) which
may indicate systemic factors. Several investigators have studied
plasma and serum lipid composition in patients using traditional
analytical methods such as thin layer chromatography (TLC) or
gas chromatography (GC) [17–18]. With the advent of sensitive
ultrahigh pressure liquid chromatography (UPLC) quadrupole
time-of-flight (Q-TOF) mass spectrometry (UPLC-MS), separation
and detection of large numbers of small molecules (metabolites) in
complex starting mixtures has become feasible. UPLC-MS
provides rapid screening with accurate mass measurement, is of
high resolution, has low-detection limits, permits ion fragmenta-
tion, and does not require a large amount of sample or a
combination of different techniques to identify metabolites. This
technology has made it possible to rapidly identify biomarkers
which distinguish normal states from various disease states using
biological specimens such as urine, plasma and serum [19–21].
We sought to use this metabolomics approach to contrast the
serum metabolome of patients with high and low bacterial indices
(BI) using UPLC-MS. In the high-BI serum we discovered greater
levels of the polyunsaturated fatty acids (PUFAs) eicosapentaenoic
acid (EPA), arachidonic acid (AA) and docosahexaenoic acid
(DHA). We discuss these findings in the context of emerging
models regarding the interactions between lipid metabolism and
immunity. The methods and findings have implications for
discovery of novel biomarkers for diagnosis, identification of
therapeutic targets and elucidation of pathogenic mechanisms.
Materials and Methods
Ethical Statement
Ethical approval for the use of these stored samples for research
was obtained from the Institutional Review Board of Colorado
State University and the Cebu Skin Clinic. Patient samples were
collected following written informed consent.
Serum Sample Collection, Preparation and Selection
Sera were selected from a sample bank generated for ongoing
research into the molecular epidemiology of leprosy involving
newly diagnosed leprosy patients at the Cebu Skin Clinic in Cebu,
Philippines [22]. Samples were taken prior to the initiation of
multidrug therapy. Blood samples were drawn into a plain (no
additive) evacuated tube (BD Vacutainer Serum) and centrifuged
at 1,500 rpm for 10 min at 4uC in a refrigerated centrifuge. The
serum samples were aliquoted into multiple vials at 1 ml per vial
and frozen at 220uC until shipment. The sera were shipped on
dry ice to Colorado State University and stored at 220uC until
subsequent use in the laboratory.
Serum samples were selected from two groups of patients, those
with BI,1 (n=10) and those with BI.4 (n=13) (Table 1). Sample
selection was randomized and without consideration of clinical or
demographic data aside from BI. Though factors such as age,
gender,clinicalpresentationandmedicalhistorywerenotconsidered
in the study design or analysis, such data were collected during
patient intake and are presented in Table 1. BI was measured at the
CebuSkinClinicbymicroscopicexaminationofacid-faststainedslit-
skin smears taken from six sites, including representative active
lesions. BI was ranked on a log 10 scale from 0 to 6 [23].
A volume of 50 ml from each serum sample was prepared for
analysis by UPLC-MS. Sera proteins were precipitated by the
addition of 3 volumes (150 ml) of cold 100% methanol. The
samples were vortexed, placed at 220uC for two hours, then
centrifuged for 10 minutes at 15,000 rpm to pellet the protein
precipitate. The supernatants were carefully transferred to new
Eppendorf tubes. From each supernatant, 1 ml was analyzed by
UPLC-MS in both negative and positive modes with duplicate
injections. To confirm the observations and mass spectrometry
methods a subset of the selected sera were reanalyzed using new
aliquots and triplicate injections. Five each from the low-BI (L32,
L40, L76, L79, L85) and high-BI (L1, L11, L19, L58, L88) groups
were pooled and retested; two low-BI (L40, L85) and two high-BI
(L15, L88) samples were retested individually.
Instrumentation and UPLC-MS Methods
The serum methanol extracts were separated on a Waters
ACQUITY UPLC coupled with a Q-TOF under the control of
MassLynx v4.1 [Waters. Millford, MA, USA]. Sample injections
(1 ml) were performed on a Waters ACQUITY UPLC system.
Separation was performed using a Waters ACQUITY UPLC C8
column (1.7 mM, 1.06100 mm), using a gradient from solvent A
(89% water, 5% acetonitrile, 5% isopropanol, 1% 500 mM
ammonium acetate) to solvent B (49.5% acetonitrile, 49.5%
isopropanol, 1% 500 mM ammonium formate). Injections were
Author Summary
Leprosy is an infectious disease caused by the obligate
intracellular bacterium Mycobacterium leprae. M. leprae
infects the skin and nerves, leading to disfigurement and
nerve damage, with the severity of the disease varying
widely. We believe there are multiple factors (genetic,
bacterial, nutritional and environmental), which may
explain the differences in clinical manifestations of the
disease. We studied the metabolites in the serum of
infected patients to search for specific molecules that may
contribute to variations in the severity of disease seen in
leprosy. We found that there were variations in levels of
certain lipids in the patients with different bacterial loads.
In particular, we found that three polyunsaturated fatty
acids (PUFAs) involved in the inhibition of inflammation
were more abundant in the serum of patients with higher
bacterial loads. However, we do not know whether these
PUFAs originated from the host or the bacteria. The
variations in the metabolite profile that we observed
provide a foundation for future research into the
explanations of how leprosy causes disease.
Increased Lipid Levels in Lepromatous Leprosy
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gradient to 40% B was applied, followed by a 10 min gradient to
100% B which was held for 3 min, then returned to starting
conditions over 0.1 min, and then allowed to re-equilibrate for
5.9 min. Flow rate was constant at140 ml/min for the duration of
the run. The column was held at 50uC; samples were held at 5uC.
Mass data were collected between 50 and 1200 m/z at a rate of
two scans per second.The voltage and temperatureparameters were
as follows: 3000 V capillary, 30 V sample cone, 2.0 V extraction
cone, 350uC desolvation temperature and 130uCs o u r c et e m p e r a -
ture. Calibration was performed prior to sample analysis via infusion
of sodium formate solution, with mass accuracy within 5 ppm. For
MS/MS, the parent ion was selected by quadrupole and fragmented
via collision-induced dissociation (CID) with argon at collision
energy of 20 eV for fatty acids and 30 eV for phospholipids.
Data Processing
UPLC-MS data were aligned, extracted and viewed using
MarkerLynx v4.1 [Waters. Millford, MA, USA]. Chromatograph-
ic peaks were detected between 0 and 28 min with a retention time
(RT) window of 0.1 min. Apex track peak detection parameters
were used, with automatic detection of peak width and baseline
noise. The spectrometric features were assigned by m/z and RT,
while the relative intensity was based on the area of all features.
Initial screening for compounds with significant differences in
abundance between the low-BI and high-BI groups was performed
by orthogonal projection onto latent structures (OPLS) with the
software SIMCA-P+ v12.0 [Umetrics. Umea ˚, Va ¨sterbotten,
Sweden], using a Po(corr) cut-off of 0.5. Further statistical analysis
was performed using several R packages within R 2.12.1 [24].
Principal component analysis (PCA) was performed using the
package stats::prcomp with both scaling and centering of the
variables. Generation of receiver operating characteristic (ROC)
curves for selected compounds was performed using the R package
pROC v1.4.3 [25]; a 95% confidence interval was generated for
sensitivity using 2,000 bootstrap replicates. For each selected
compound, histogram bins were calculated using the Freedman-
Diaconis rule and kernel density estimates were calculated using
Gaussian smoothing. In order to compare the first (individual
serum) and second (pooled sera) runs, data for each compound was
Table 1. Patient demographic and clinical data.
Sample
a BI
b R-J Class
c PB/MB
d Sex Age Duration of Symptoms
e Medical History
f
Low-BI
L5 0.33 BT MB F 20 2 Y -
L32
g 0.17 BT MB M 27 1 Y -
L40
g 0.50 - MB M 38 - -
L49 0.00 BT PB M 36 2 Y -
L74 0.33 BT MB M 62 5 M Hypertension
L76 0.50 BL MB M 64 5 M -
L77 0.00 BT PB M 36 10 Y -
L79 0.00 BT PB F 64 2 Y -
L85 0.17 BL MB F 42 5 M -
L90 0.00 BT MB F 24 2 Y -
High-BI
L1 4.80 LL MB M 26 2 Y -
L9 4.70 LL MB M 25 5 Y -
L11 4.80 LL MB F 22 15 Y Congenital deformities
L15 5.00 LL MB M 25 2 Y -
L19 4.80 LL MB M 28 6 Y Appendicitis
L22 5.00 LL MB M 41 3 Y Peptic Ulcer
L29 4.80 LL MB M 18 3 Y -
L51 5.00 LL MB M 61 5 Y -
L53
h 5.00 LL MB M 39 4 Y -
L58 5.00 LL MB M 37 2 Y -
L75 5.00 LL MB M 26 2 Y -
L88 5.00 LL MB M 49 3 Y -
L89 5.00 LL MB M 30 1 Y -
aSample names are as per Sakamuri et al, 2009 [22].
bBacterial index determined from slit-skin smear [23].
cRidley-Jopling classification of leprosy [5].
dClinical classification into either paucibacillary (PB) or multibacillary (MB) leprosy.
eSelf-reported duration of symptoms prior to treatment.
fSelf-reported medical history; reported conditions do not reflect current illness at the time of diagnosis with leprosy.
gPatients who presented at the clinic in a type 1 reaction state.
hPatients with deformities caused by leprosy.
doi:10.1371/journal.pntd.0001303.t001
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the standard deviation (standard score) to account for shifts in
instrument sensitivity over time; the data were then compared for
statistically significant differences using the Mann-Whitney test.
Identification of Compounds
Tentative compound class assignments (free fatty acid, glycer-
olipid, phospholipid, etc.) were made by querying the exact mass
against the LIPID MAPS database [26] and the online web server
MassTRIX: Mass Translator into Pathways [27]. The compounds
that showed significant differences in intensity between the low-BI
and high-BI groups, based on exact m/z and 0.05 min RT
differences, were further fragmented by MS/MS in both positive
and negative ion modes. Metabolite identities were manually
examined for signature ions and verified by comparing the
fragment spectra to those in LIPID MAPS and published data
[28]. MassTRIX was also used to explore related pathways that
may be associated with selected metabolites.
Standards
After preliminary assignments were made for some of the
selected compounds, pure standards were obtained and analyzed
by the previously described chromatographic methods. Pooled
sera were rerun along side the standards. Eicosapentaenoic acid
(EPA, 20:5), arachidonic acid (AA, 20:4) and docosahexaenoic
acid (DHA, 22:6) were purchased from Sigma-Aldrich [Saint
Louis, MO, USA]; 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phos-
phocholine (PAPC) was purchased from Avanti Polar Lipids
[Alabaster, Alabama, USA]. All standards were dissolved in 75%
methanol prior to UPLC-MS analysis.
Results
Global Characterization of Mass Spectrometry Data
The UPLC-MS data were first characterized globally. Across
both the low-BI (n=10) and high-BI (n=13) samples a total of
1668 features in the positive mode and 2489 features in negative
mode were observed (Supplement S1). A PCA, generated from
abundance data of all positive and negative mode m/z-RT pairs
(features), showed low-BI and high-BI patient sera clustering away
from each other (Figure 1). The separation of patient groups
indicates that there are m/z-RT pairs that are quantitatively
distinct in the two groups. Close clustering of injection duplicates is
also seen, which is the expected behavior.
Selection and Validation of Metabolite Biomarkers
To identify the compounds that distinguished the low-BI from
high-BI samples, the dataset was first pared down to features
which exhibited the greatest difference in abundance between the
two sample groups with OPLS (not shown). This yielded 48
features with masses up to approximately 1 kDa: 19 from the
positive mode and 29 from the negative mode. From these 48
features, 18 compounds were tentatively identified using the online
databases LIPID MAPS and MassTRIX (Table 2). The data
indicate an increase in the level of several lipids in the high-BI sera
compared to those in the low-BI sera. All of the 18 identified
compounds were more abundant in the high-BI samples except for
those with m/z 518.3245, 558.3196 and 566.3192, which were
more abundant in the low-BI samples. A confirmatory second
UPLC-MS analysis was performed using a pooled subset of
samples. Though m/z and RT values shifted slightly, due to
expected operational variability, we found the same 18 com-
pounds again showed quantitative distinctions between low-BI and
high-BI groups.
We also queried the complete list of m/z values against the
MassTRIX annotation system, which performs a search for
potential compound identities and associated pathways curated in
KEGG: Kyoto Encyclopedia of Genes and Genomes [29].
MassTRIX assigned a total of 74 negative mode features to 143
compounds in 40 pathways, and 79 positive mode features to 89
compounds in 51 pathways. The predominant hits were pathways
involved in AA metabolism (29 compounds) and synthesis of
unsaturated fatty acids (13 compounds); not all compounds were
unique.
Compound Identification by Tandem Mass Spectrometry
The 18 significant compounds that we tentatively identified
were further characterized by MS/MS. From these 18 com-
pounds, the compounds of the most interest to us - given their role
in modulation of the inflammatory response - were the n-6 PUFA
AA, the n-3 PUFAs EPA and DHA, and the compound with
structural similarity to PAPC. Commercial standards of EPA, AA,
DHA and PAPC were obtained and submitted to mass
spectrometry in parallel with the serum samples. Not all of the
18 ions fragmented, but compound confirmation was achieved via
MS/MS for 9 compounds by referencing the ion fragmentation
pattern against published spectra and/or available standards
(Table 2) [30–31].
The chemical structures and fragmentation patterns of
compounds listed in Table 2 are shown in Figures 2, 3, 4
and Supplements S2, S3. In each of Figures 2, 3, 4 and
Supplement S2 the chemical structure of the compound is
shown in Panel A, the fragmentation pattern of the commercial
standard is shown in Panel B, and the fragmentation pattern of
the corresponding compound in the pooled serum sample is shown
Figure 1. Principal component analysis of all positive and
negative mode m/z values detected in serum of leprosy
patients. A PCA score plot of all positive mode (n=1668) and negative
mode (n=2489) m/z values collected from UPLC-MS analysis of 23
serum samples (10 low-BI, 13 high-BI). The first two components
account for 20.4% of the variation in the data. Duplicate runs of each
sample are visible as clustered pairs. A separation of samples is seen
based on the BI of the patient.
doi:10.1371/journal.pntd.0001303.g001
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Increased Lipid Levels in Lepromatous Leprosy
www.plosntds.org 5 September 2011 | Volume 5 | Issue 9 | e1303in Panel C. Supplement S3 shows the fragmentation pattern in
the pooled serum sample for the remaining compounds putatively
identified by MS/MS. The spectra illustrations have been adjusted
from the original MassLynx output files for clarity; the font of the
axes and labels has been changed, the line width of the spectra has
beenincreased,andextraneoustextandbordershavebeenremoved.
The parent and daughter ions of EPA, AA and DHA appear as
expected in both the standards and patient samples. However, we
could not conclusively identify the feature we observed in the
serum samples with m/z of 798. The molecular weight of PAPC is
781, with an observed value of 766 under negative ionization due
to loss of the methyl group from choline (Supplement S2B). The
feature with m/z of 798 produced several fragments consistent
with the PAPC standard; specifically, ions with m/z 255, 303 and
480 (Supplement S2C), which correspond to palmitic acid,
arachidonic acid and lysophosphocholine (16:0/0:0), respectively.
The RT for the PAPC standard was 8.5 min, while the RT for the
feature with m/z 798 was 4.3 min. It is possible, but not
confirmed, that the observed feature with an m/z of 798 is an
oxidized form of PAPC [32]; additional investigation was
performed, but did not yield satisfactory results.
Statistical Support for Biomarkers
The diagnostic accuracy of each feature, as measured by the
extent to which each feature accurately distinguishes low-BI from
high-BI samples, was determined using receiver operating
characteristic (ROC) curves [33]. The ROC curve for the feature
compares the distribution of abundance between low-BI and high-
BI samples. The more the curve is pulled toward the upper-left
corner [higher sensitivity, higher specificity and higher area under
the curve (AUC)] the less overlap between the distributions in each
group, and thus the more effective the feature is at discriminating
low-BI from high-BI sera. The AUC for each significant feature,
along with a 95% confidence interval indicated as a 6 value, is
shown in Table 2. ROC curves for features of interest are shown
in Panel D of Figures 2, 3, 4 and Supplement S2.
Figure 2. Eicosapentaenoic acid (EPA) chemical structure, MS/MS spectra, ROC curve and distribution across sample groups. (A) The
chemical structure of EPA. (B) The MS/MS fragmentation pattern for the commercial standard. (C) The MS/MS fragmentation pattern of a
representative pooled serum sample. (D) An ROC curve, showing the diagnostic accuracy of EPA in distinguishing low-BI from high-BI samples. The
shaded (red) region surrounding the curve represents a 95% confidence interval for sensitivity. The AUC is shown on the graph with a 95%
confidence interval in parenthesis. (E) A histogram showing the distribution of EPA in the low-BI and high-BI groups. The overlaid curves show the
kernel density estimates for each sample group.
doi:10.1371/journal.pntd.0001303.g002
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www.plosntds.org 6 September 2011 | Volume 5 | Issue 9 | e1303The distribution of abundance values of the individual samples
(first experiment) can be seen in Panel E of Figures 2, 3, 4 and
Supplement S2, as both a histogram and kernel density estimate.
In addition to comparing the abundance values across patient
groups, we also compared the first (individual sample) and second
(pooled sample) experiments for statistically significant differences.
Although the same qualitative differences were seen across patient
groups in both experiments, the two experiments showed marked
differences in mean abundance values, which we believe is due to
variation in instrument sensitivity between runs. The distribution of
abundance values between experiments was compared using the
Mann-Whitney test following standardization to account for
variation between runs. Between the two experiments, the
distributions for EPA (low-BI p=0.15, high-BI p=0.07;
Figure 2E), AA (low-BI p=0.65, high-BI p=0.34; Figure 3E),
DHA (low-BI p=0.83, high-BI p=0.53; Figure 4E) and the
PAPC-like compound (low-BI p=0.62, high-BI p=0.38; Supple-
mentS2E)werenotfoundtodiffersignificantlyat95%confidence.
We note that there is a sampling bias with regards to both age
and sex in the selected patients (Table 1). Specifically, the
median age is 37 in the low-BI and 28 in the high-BI, and the
ratio of male to female is 6:4 in the low-BI and 12:1 in the high-
BI. The parent study from which these patients were randomly
selected (n=310) shows a concordant bias. In the parent study,
the median age of a low-BI patient (n=63) is 37 and the median
age of a high-BI patient (n=123) is 29. The odds of selecting a
male patient from the low-BI group are 37:26 (1.42), and the
odds of selecting a male patient from the high-BI group are
111:12 (9.25). Though patient age and sex were not considered
in the study design or the analysis as a whole, we investigated the
diagnostic accuracy of the features listed in Table 2 when
considering only the male patients. Though some shifts were
seen in the AUC and median abundance in the two BI groups,
the same set of features still showed statistically significant
differences between the low-BI and high-BI groups (data not
shown).
Figure 3. Arachidonic acid (AA) chemical structure, MS/MS spectra, ROC curve and distribution across sample groups. (A) The
chemical structure of AA. (B) The MS/MS fragmentation pattern for the commercial standard. (C) The MS/MS fragmentation pattern of a
representative pooled serum sample. (D) An ROC curve, showing the diagnostic accuracy of AA in distinguishing low-BI from high-BI samples. The
shaded (red) region surrounding the curve represents a 95% confidence interval for sensitivity. The AUC is shown on the graph with a 95%
confidence interval in parenthesis. (E) A histogram showing the distribution of AA in the low-BI and high-BI groups. The overlaid curves show the
kernel density estimates for each sample group.
doi:10.1371/journal.pntd.0001303.g003
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The goal of our research was to explore the applicability of non-
targeted metabolomics to the study of leprosy. Most research
aimed at understanding variations in clinical presentations have
been studies of gene expression profiles and immune response
mechanisms using a variety of assays on whole blood, serum,
plasma, peripheral blood mononuclear cells or skin biopsies
[17,34–36]. To date, metabolite profiles in leprosy have only been
explored using target-based assays of blood samples [37–38].
These techniques are limited in terms of sample throughput, the
ability to resolve individual metabolites in complex specimens, the
sensitivity of feature detection, and the accuracy of compound
identification. By using a metabolomics approach based on mass
spectrometry, we were able to discover several metabolites in
serum with differential levels in low-BI and high-BI patient groups.
In particular, we found that in the high-BI group there was a
statistically significant increase in abundance of the n-3 PUFAs
EPA and DHA, and the n-6 PUFA AA. The identification of
differential levels of PUFAs in high-BI patients is intriguing, as
lipid metabolism and lipid mediators have been implicated in
many disease models, both infectious and non-infectious.
It has been widely thought that n-3 PUFAs (DHA and EPA) are
beneficial to human health, because of their association with
mitigation of the inflammatory response in conditions such as
autoimmune disorders, heart disease, arthritis and graft-versus-
host disease [13,39–40]. Conversely, the n-6 PUFAs (including
AA) are generally considered deleterious in chronic diseases
because they exert pro-inflammatory effects [39]. Ironically, it is
this pro-inflammatory property that would provide the necessary
anti-microbial activity to combat bacterial infections.
However, new research indicates that this is only a generalized
model for the properties of the n-6 versus n-3 PUFAs. Consensus is
absent on their strict pro- versus anti-inflammatory phenotypes,
due to their interconnected metabolic pathways and the
production of downstream products (eicosanoids). Recent studies
Figure 4. Docosahexaenoic acid (DHA) chemical structure, MS/MS spectra, ROC curve and distribution across sample groups.
(A) The chemical structure of DHA. (B) The MS/MS fragmentation pattern for the commercial standard. (C) The MS/MS fragmentation pattern of a
representative pooled serum sample. (D) An ROC curve, showing the diagnostic accuracy of DHA in distinguishing low-BI from high-BI samples. The
shaded (red) region surrounding the curve represents a 95% confidence interval for sensitivity. The AUC is shown on the graph with a 95%
confidence interval in parenthesis. (E) A histogram showing the distribution of DHA in the low-BI and high-BI groups. The overlaid curves show the
kernel density estimates for each sample group.
doi:10.1371/journal.pntd.0001303.g004
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that they had both pro- and anti-inflammatory roles. Deckelbaum
and Calder found that prostaglandin E2 (PGE2) may inhibit the
production of pro-inflammatory cytokines (TNF-a and IL-1) from
monocytes and macrophages [41]. They also found that PGE2
inhibits production of leukotrienes (LTs), through control of 5-
lipoxygenese, and induces production of lipoxins, through 15-
lipooxygenase; leading to anti-inflammatory and pro-resolution
activities by the action of lipoxins [41]. Based on these results, AA
n-6 PUFAs may control the inflammatory response by regulating
both the pro- and anti-inflammatory cytokine networks. It has also
been suggested that both n-3 and n-6 PUFAs play an anti-
inflammatory role due to inactivation of reactive oxygen species by
the unsaturated double bond. Furthermore, PUFAs may bind to
peroxisome proliferator activated receptors, thus interfering with
signaling molecules such as NF-kB, and repressing transcription of
a variety of genes [42]. Zeyda et al found that both n-3 and n-6
PUFAs inhibit cytokine production (TNF-a and IL-12), T cell
stimulation and dendritic cell differentiation at the gene level.
PUFA treated dendritic cells were shown to be associated with
altered membrane lipid composition, specifically an increase in
unsaturated lipids, which implicates AA and EPA as anti-
inflammatory mediators [14]. In the mycobacterial disease models,
enrichment of n-3 PUFAs enhances susceptibility to Mycobacterium
tuberculosis infection in vitro (infected macrophages) [43–44]. Anes et
al showed that the pro-inflammatory effect of AA promotes
increased bacteria killing inside macrophages by stimulating
phagosomal actin assembly. In contrast, the same authors also
showed that EPA and DHA promote bacterial survival and growth
inside macrophages by lowering the levels of pro-inflammatory
cytokines (IFN-c, TNF-a, IL-1 and IL-6), weakening the oxidative
response and hindering phagosome maturation [45].
In leprosy, Cruz et al postulated that the fatty acids and
phospholipids which accumulate in lepromatous lesions are of host
origin. They found a pronounced upregulation of host genes
involved in lipid metabolism, such as phospholipase A2 (PLA2)
and phospholipase C (PLC), for which functional counterparts are
not encoded in the M. leprae genome [16]. An increase in
phospholipase activity may contribute to the increased serum
levels of AA we observed in our high-BI patients; PLA2 catalyzes
the hydrolysis of phospholipids to release arachidonate in a single-
step reaction, and PLC generates diacylglycerols, from which AA
can be subsequently released by diacylglycerol- and monoacylgly-
cerol-lipases.
Several other metabolites which modulate immunity either for
or against mycobacterial survival have been described in the
literature. These include cholesterol (HDL or LDL derived),
triglycerides and vitamin D [17–18,46–47]. We did not observe
differential levels of these metabolites in our patient groups,
though this does not imply variations were not present. The nature
of the starting sample and the fractionation conditions may affect
the metabolite pools; this study was based only on a simple one-
step methanol extraction followed by C8 reverse phase UPLC-
MS. Lysophosphatidylcholines (Lyso PCs) have been shown to
have a potential role in immunomodulation, particularly pro-
inflammatory functions [48]. We tentatively assigned some
significant features as Lyso PCs - three of which were more
abundant in the low-BI sera (Table 2). However, these
identifications are preliminary and unconfirmed at his stage.
In this study we focused solely on identifying compounds with
differential levels in patient sera based on the quantitative criterion
of BI, rather than the more qualitative Ridley-Jopling and
paucibacillary/multibacillary systems which are not always
consistent across clinics [49]. Sex was not a controlled factor in
our study. Though our results do not specifically indicate whether
the serum signatures we found can be explained by sex differences,
there is an inherent sex bias in leprosy [3], as also evidenced in our
sample sets. Further investigations which delve into whether there
are specific metabolites that differentiate leprosy patients based
upon other classification criteria, such clinical presentation, sex,
age or genetics, would provide valuable insight into the intrinsic
biological factors that contribute to bacterial growth in leprosy.
The metabolomic fingerprint we identified - higher levels of AA,
DHA and EPA in the sera of high-BI leprosy patients - is
consistent with diminished host innate immunity to infection [16];
reaffirming the role of altered host lipid metabolism in infection
and immunity. The increased serum levels of n-3 and n-6 PUFAs
we identified in high-BI patients may promote M. leprae survival
through inhibition of both the innate and adaptive immune
response of the host. These novel preliminary findings lend
themselves to pathway specific genome expression analysis and
further characterization of the AA derived lipid mediators. For
instance, the leukotriene A4 hydrolase (lta4h) gene has been
implicated as a susceptibility locus in leprosy and tuberculosis [50].
It is thought that the fine balance of lipoxin B4 and leukotriene B4
controls the propensity to infection or immunity. Of the 9
compounds we identified by MS/MS, those with m/z 317 and 335
are candidate AA derivatives suitable for further analysis. A
longitudinal study that employs a metabolomics approach may
shed light on the origins and dynamics of the lipid profile. By
collecting and analyzing sera before multidrug therapy, during
treatment, at the onset of reaction states and after the patient is
released, we may discover fluctuations in the lipid profile over the
course of the infection; enabling the ultimate aim of improving
diagnostics, treatment options and creating a deeper understand-
ing of the pathogenesis of leprosy.
Supporting Information
Supplement S1 Complete table of all features observed
in positive and negative mode UPLC-MS. A total of 1668
features in the positive mode and 2489 features in negative mode
are listed for the individual (non-pooled) sample set. RT, m/z and
integrated peak intensities are shown for each feature. Sample
injection duplicates are identified after the sample name (N1, N2
or P1, P2).
(XLS)
Supplement S2 1-palmitoyl-2-arachidonoyl-sn-phospha-
tidylcholine (PAPC) chemical structure, MS/MS spectra,
ROC curve and distribution across sample groups.
(A) The chemical structure of PAPC. (B) The MS/MS
fragmentation pattern for the PAPC commercial standard. (C)
The MS/MS fragmentation pattern for compound structurally
similar to PAPC from a representative pooled serum sample. (D)
An ROC curve, showing the diagnostic accuracy of the PAPC-like
compound in distinguishing low-BI from high-BI samples. The
shaded (red) region surrounding the curve represents a 95%
confidence interval for sensitivity. The AUC is shown on the graph
with a 95% confidence interval in parenthesis. (E) A histogram
showing the distribution of the PAPC-like compound in the low-BI
and high-BI groups. The overlaid curves show the kernel density
estimates for each sample group.
(PDF)
Supplement S3 Spectra for additional compounds iden-
tified by MS/MS. (A) The MS/MS fragmentation pattern for
the compound with m/z 317.21. (B) The MS/MS fragmentation
pattern for the compound with m/z 329.25. (C) The MS/MS
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www.plosntds.org 9 September 2011 | Volume 5 | Issue 9 | e1303fragmentation pattern for the compound with m/z 335.22. (D)
The MS/MS fragmentation pattern for the compound with m/z
516.31. (E) The MS/MS fragmentation pattern for the compound
with m/z 558.32.
(PDF)
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